in Money

Allergan, in Shift From Buying Spree, Considers a Spin-Off.


By MICHAEL J. de la MERCED

The drugmaker had built itself into a $124 billion powerhouse in large part through repeated deals, for companies like Forest Laboratories.

Published: July 25, 2015 at 12:00AM

from NYT Business Day. Read more at: http://ift.tt/1IjU6fU

Subscribe
Notify of

Write a Comment

Comment

guest
0 Comments
Newest
Oldest Most Voted
Inline Feedbacks
View all comments
  • Related Content by Tag